Illumina (ILMN) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Illumina (ILMN) has outperformed Natera (NTRA) over the past year, gaining 55.7% versus a gain of 18.5%. Over five years, NTRA leads with a +188.8% price change compared with -46.4% for ILMN. Natera is the larger company by market cap ($39.64 billion vs $29.15 billion), about 1.4 times the size.
Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | NTRA |
|---|---|---|
| Share price | $192.82 | $273.40 |
| Market cap | $29.15B | $39.64B |
| 1-day change | -3.90% | -5.70% |
| YTD return | +47.01% | +19.34% |
| 1-year return | +55.69% | +18.54% |
| 5-year return | -46.40% | +188.82% |
| P/E ratio (TTM) | 33.19 | — |
| Forward P/E | 31.19 | — |
| EPS (TTM) | $5.81 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.34B | $2.31B |
| Revenue growth (YoY) | -0.66% | +35.90% |
| Net income (latest FY) | $850.00M | $-208.16M |
| Gross margin | 66.08% | — |
| Operating margin | 18.58% | -13.44% |
| Net margin | 19.57% | -9.03% |
| 52-week high | $309.35 | $437.41 |
| 52-week low | $112.65 | $181.00 |
| Distance from 52-week high | -37.67% | -37.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +35.59% | +50.06% |
| Average volume | 2.82M | 1.77M |
| Shares outstanding | 151.20M | 145.00M |
| Employees | 8,600 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed NTRA by 37.1 percentage points over the past year.
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs -0.66%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
ILMN vs NTRA FAQ
Which is bigger, Illumina or Natera?
Natera (NTRA) is larger, with a market capitalization of $39.64B compared with $29.15B for Illumina (ILMN).
Which stock has performed better over the past year, ILMN or NTRA?
ILMN returned +55.69% over the past 12 months, compared with +18.54% for NTRA (price return, excluding dividends). Past performance does not predict future results.
Are Illumina and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.